Glaucoma neuroprotection moves into clinical trials

Implant shows significant increase in nerve fibre layer thickness

Glaucoma neuroprotection moves into clinical trials
Howard Larkin
Howard Larkin
Published: Friday, October 18, 2019
Jeffrey L Goldberg MD, PhD
Innovative study designs and integrating therapeutic testing with biomarkers have advanced several neuroprotective and neuroenhancement compounds to clinical trials, which could advance glaucoma therapy beyond prevention through IOP control, Jeffrey L Goldberg MD, PhD, told AAO 2019 Glaucoma Subspecialty Day in San Francisco, USA. Interim analysis of a phase II trial of Ciliary Neurotrophic Factor implant shows a statistically significant increase in nerve fibre layer thickness and a trend toward better visual fields with no treatment-limiting adverse effects after one year, said Dr Goldberg, who is professor and chair of ophthalmology at Stanford University, Palo Alto, California, USA. An eight-week phase I/II randomised clinical trial of nerve growth factor eye drops also has been conducted, as has a successful phase Ib randomised study of an anti-C1q intravitreal injection for glaucoma. A phase Ib randomised study of virtual reality visual stimulation approach using VR goggles to stimulate RGC cells or balancing inter-eye competition is also in the works. These studies can produce results in a shorter time than previous neuroprotection studies by focusing on rapidly progressing patients and clustering visual field tests to hedge against variability in 12- to 18-month tests, and studying sick, but not dead, RGCs in shorter neuroenhancement studies, Dr Goldberg said. Both types incorporate new exploratory biomarkers.
Tags: biomarkers, glaucoma, AAO 2019
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...